Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management.

摘要: Background The definitive use of 18F-2-deoxy-d-glucose positron emission tomography (FDG-PET) to detect nodal metastasis in patients with early-stage non-small cell lung cancer (NSCLC) being evaluated for local nonsurgical management, such as stereotactic body radiation therapy and minimally invasive percutaneous ablative therapies, underscores the importance diagnosing N1 disease by FDG-PET. purpose this study was evaluate FDG-PET detection determine if FDG-PET–positive predicts poor survival pathologic stage II-N1 NSCLC. Methods We reviewed all who underwent surgical resection at MD Anderson Cancer Center from 2000 2011 had T1 T2 a preoperative compared clinicopathologic characteristics PET-positive PET-negative disease. Results A total 104 met inclusion criteria. 87 IIA (T1a N1, T1b or T2a N1) 17 IIB (T2b N1). Only 25 (24%) There no clinical difference between No significant found rates groups ( p  = 0.9). Conclusions has sensitivity detecting disease, N1-positive on does not have an effect survival. should be used alone management management.